Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy

Molecular Medicine Today

Volumn 4, Issue 7, 1998, Pages 305-312

  Romero, Pedro ^a   Cerottini, Jean Charles ^a   Waanders, Gary A ^b  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^b Diagnocure   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

T LYMPHOCYTE RECEPTOR;

ADOPTIVE TRANSFER; ANALYTIC METHOD; ANTIGEN DETECTION; ANTIGEN SPECIFICITY; CANCER IMMUNOTHERAPY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DIAGNOSTIC APPROACH ROUTE; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR INTERACTION; REVIEW; SINGLE STRAND CONFORMATION POLYMORPHISM;

ANTIGENS, NEOPLASM; HUMANS; IMMUNOLOGIC TECHNIQUES; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0031880570     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(98)01280-5     Document Type: Review

References (48)

1. van der Bruggen P.et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 254:1991;1643-1647.
2. Coulie P. Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines. Mol. Med. Today. 3:1997;261-268.
3. Boniface J.J., Davis M.M. T-cell recognition of antigen. A process controlled by transient intermolecular interactions. Ann. New York Acad. Sci. 766:1995;62-69.
4. Rivoltini L.et al. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol. 154:1995;2257-2265.
5. Jäger E.et al. Generation of cytotoxic T cell responses with synthetic melanoma associated peptides in vivo, implications for tumor vaccines with melanoma associated antigens. Int. J. Cancer. 66:1996;162.
6. Yee C., Riddell S.R., Greenberg P.D. Prospects for adoptive T cell therapy. Curr. Opin. Immunol. 9:1997;702-708.
7. Sharrock C.E., Kaminski E., Man S. Limiting dilution analysis of human T cells: a useful clinical tool. Immunol. Today. 11:1990;281-286.
8. Taswell C. Limiting dilution assay for the determination of immunocompetent cell frequencies. I. Data analysis. J. Immunol. 126:1981;1614-1620.
9. 51Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology. 14:1968;181-196.
10. Marchand M.et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int. J. Cancer. 63:1995;883-885.
11. Tsang K.Y.et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl. Cancer Inst. 87:1995;982-990.
12. Salgaller M.L., Marincola F.M., Cormier J.N., Rosenberg S.A. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res. 56:1996;4749-4757.
13. Cormier J.N.et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan-A. Cancer J. Sci. Am. 3:1997;37-44.
14. Romagnani S. Biology of human Th1 and Th2 cells. J. Clin. Immunol. 15:1995;121-129.
15. Carter L.L., Swain S.L. Single cell analyses of cytokine production. Curr. Opin. Immunol. 9:1997;177-182.
16. Hoefakker S., Boersma W.J., Claassen E. Detection of human cytokines in situ using antibody and probe based methods. J. Immunol. Methods. 185:1995;149-175.
17. Jung T.et al. Detection of intracellular cytokines by flow cytometry. J. Immunol. Methods. 159:1993;197-207.
18. Prussin C., Metcalfe D.D. Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti-cytokine antibodies. J. Immunol. Methods. 188:1995;117-128.
19. + T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. J. Clin. Invest. 99:1997;1739-1750.
20. Fonteneau J.F.et al. Heterogeneity of biologic responses of melanoma-specific CTL. J. Immunol. 159:1997;2831-2839.
21. + T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens. J. Immunol. Methods. 191:1996;131-142.
22. Scheibenbogen C.et al. Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay. Int. J. Cancer. 71:1997;932-936.
23. Herr W.et al. The use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens. J. Immunol. Methods. 203:1997;141-152.
24. Casanova J.L., Maryanski J.L. Antigen-selected T-cell receptor diversity and self-nonself homology. Immunol. Today. 14:1993;391-394.
25. Kalams S.A.et al. Longitudinal analysis of T cell receptor (TCR) gene usage by human immunodeficiency virus 1 envelope-specific cytotoxic T lymphocyte clones reveals a limited TCR repertoire. J. Exp. Med. 179:1994;1261-1271.
26. Argaet V.P.et al. Dominant selection of an invariant T cell antigen receptor in response to persistent infection by Epstein-Barr virus. J. Exp. Med. 180:1994;2335-2340.
27. Lehner P.J.et al. Human HLA-A0201-restricted cytotoxic T lymphocyte recognition of influenza A is dominated by T cells bearing the Vβ 17 gene segment. J. Exp. Med. 181:1995;79-91.
28. Pannetier C., Even J., Kourilsky P. T-cell repertoire diversity and clonal expansions in normal and clinical samples. Immunol. Today. 16:1995;176-181.
29. Cole G.A., Hogg T.L., Woodland D.L. The MHC class I-restricted T cell response to Sendai virus infection in C57BL/6 mice: a single immunodominant epitope elicits an extremely diverse repertoire of T cells. Int. Immunol. 6:1994;1767-1775.
30. Sensi M.et al. Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1. Proc. Natl. Acad. Sci. U. S. A. 92:1995;5674-5678.
31. Romero P.et al. Multiple specificities in the repertoire of a melanoma patient's cytolytic T lymphocytes directed against tumor antigen MAGE-1.A1. J. Exp. Med. 182:1995;1019-1028.
32. Romero P.et al. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201 restricted Melan-A/MART-1 antigenic peptide in melanoma. J. Immunol. 159:1997;2366-2374.
33. Mackensen A.et al. Direct evidence to support the immunosurveillance concept in a human regressive melanoma. J. Clin. Invest. 93:1994;1397-1402.
34. Sensi M.et al. Clonal expansion of T lymphocytes in human melanoma metastasis after treatment with a hapten-modified autologous tumor vaccine. J. Clin. Invest. 99:1997;710-717.
35. Waanders G.et al. Melanoma-reactive human cytolytic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line. Clin. Cancer Res. 3:1997;685-696.
36. Miescher S.et al. Preferential clonogenic deficit of CD8-positive T lymphocytes infiltrating human solid tumors. Cancer Res. 48:1988;6992-6998.
37. -T cell population. J. Immunol. 144:1990;1696-1704.
38. Bieganowska K.D.et al. Direct ex vivo analysis of activated, fas-sensitive autoreactive T cells in human autoimmune disease. J. Exp. Med. 185:1997;1585-1594.
39. Altman J.D.et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 274:1996;94-96.
40. Murali-Krishna K.et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity. 8:1998;177-187.
41. Parkhurst M.R.et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified HLA-A*0201-binding residues. J. Immunol. 157:1996;2539-2548.
42. Bakker A.B.H.et al. Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope. Int. J. Cancer. 70:1997;302-309.
43. Valmori D.et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogs. J. Immunol. 160:1998;1750-1758.
44. Luescher I.F.et al. HLA photoaffinity labeling reveals overlapping binding of homologous MAGE peptides by HLA-A1, HLA-29 and HLA-B44. J. Biol. Chem. 271:1996;12463-12471.
45. Moretta A.et al. Quantitative assessment of the pool size and subset distribution of cytolytic T lymphocytes within human resting or alloactivated peripheral blood T cell populations. J. Exp. Med. 158:1983;571-585.
46. Hoffenbach A.et al. Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans. J. Immunol. 142:1989;452-462.
47. Coulie P.G.et al. Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells. Int. J. Cancer. 50:1992;289-297.
48. Nelson E.L.et al. Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma. Blood. 88:1996;580-589.